FBIOFortress Biotech, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $2.46 · now $2.51 (2026-09-17, +2.0% since)

Based on its own history, a month from the 2026-09-16 close, FBIO has typically landed between $1.69 and $3.43 — a range of −31.5% to +39.4% from the issuance price $2.46.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

3,705 overlapping 1 month windows · 2011-11-17 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($2.46) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where FBIO has typically landed a month from the 2026-09-16 close of $2.46 — the range is history, not a prediction.

$1.69worst · -31.5%$3.43best · +39.4%
  • now $2.51 (+2.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.34 (-4.7%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.03–$2.66
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.69–$3.43
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 3,706 windows spanning 2011-11-17 to 2026-09-17. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2013-10-08−81.7%−81.7%+0.0%
2013-10-09−79.9%−81.1%+0.0%
2013-10-10−79.2%−80.2%+0.0%
3 best
2023-11-14+150.8%+0.0%+150.8%
2023-11-13+147.0%−1.5%+147.0%
2023-11-10+145.0%+0.0%+151.9%

3,706 overlapping windows · 2011-11-17 – 2026-09-17 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~15 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
40%
+9.2%
n=15
Feb
67%
+3.2%
n=15
Mar
47%
+2.4%
n=15
Apr
33%
−4.1%
n=15
May
40%
−2.0%
n=15
Jun
27%
−2.6%
n=15
Jul
53%
−0.5%
n=15
Aug
60%
+6.2%
n=15
Sep
20%
−6.7%
n=15
Oct
29%
−19.4%
n=14
Nov
71%
+10.6%
n=14
Dec
53%
+7.6%
n=15

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$4$2↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

20 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-22Jin DaviddirectorAward / grant400,0001,651,571Form 4
2026-04-01Jin DaviddirectorAward / grant2,9671,251,571Form 4
2026-03-18WEISS MICHAEL SdirectorAward / grant475,4242,276,562Form 4
2026-03-18ROSENWALD LINDSAY A MDdirectorAward / grant475,4244,586,841Form 4
2026-01-01Lorenz KevindirectorAward / grant27,322101,009Form 4
2026-01-01LOBELL J JAYdirectorAward / grant27,322192,397Form 4
2026-01-01Klein DovdirectorAward / grant27,322130,105Form 4
2026-01-01Hoenlein MalcolmdirectorAward / grant27,322115,747Form 4
2026-01-01Harvey JimmiedirectorAward / grant27,322146,704Form 4
2025-10-01Jin DaviddirectorAward / grant2,7111,248,604Form 4
2025-04-01Jin DaviddirectorAward / grant5,0001,245,893Form 4
2025-01-01Hoenlein MalcolmdirectorAward / grant49,38388,425Form 4
2025-01-01Klein DovdirectorAward / grant49,383102,783Form 4
2025-01-01LOBELL J JAYdirectorAward / grant49,383165,075Form 4
2025-01-01Lorenz KevindirectorAward / grant49,38373,687Form 4
2025-01-01Lu LucydirectorAward / grant49,38361,273Form 4
2025-01-01Harvey JimmiedirectorAward / grant49,383119,382Form 4
2025-01-01WEISS MICHAEL SdirectorAward / grant454,1531,801,138Form 4
2025-01-01ROSENWALD LINDSAY A MDdirectorAward / grant454,1534,111,417Form 4
2024-12-19Jin DaviddirectorAward / grant1,000,0001,240,893Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.